This is a snippet of the transcript, sign up to read more.
It is more the fragmented market because customers choose NGS services based on price and convenience. West Coast customers prefer not to send samples to Genewiz who is on the East Coast, so they will choose a local service provider to do their sequencing. Genewiz is advantaged by their size and capabilities, and customers still use them regardless of the location because they provide a reliable timeline. Local service providers cannot always stick to their promises when their lab is short staffed. I work with pharmaceutical companies and academic researchers, and the latter prefer to use their core. Pharmaceutical companies are also building genomics cores in their facilities running multiple sequencers; they do it in-house instead of outsourcing it.
This is a snippet of the transcript, sign up to read more.
Several reasons; price and the ability to scale. Pharmaceutical companies have worked with Genewiz for years because they are close to them in New Jersey and Boston. Genewiz provides good service because they only hire PhDs as their study managers. Once a company confirms a project with Genewiz, they assign that to data managers who also project manage the account. They have a dedicated team who can communicate science to customers. That team is strict and well-trained to ensure the best customer service. In terms of a unique selling point from Genewiz, there are no new innovations, but they are consistent with good delivery and service.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.